The evolution of thalidomide and its IMiD derivatives as anticancer agents

By J. Bartlett, K. Dredge, A. Dalgleish. Nature Reviews. Cancer, 2004

788 citations recorded by the source corpus.

Subfields: Urban Studies

View Paper: https://www.semanticscholar.org/paper/495ed08ead797d42f9750ae2e64a32d3ff6ec88b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Narla
2. Benjamin L. Ebert

Citations in the corpus

• Ribosomopathies: human disorders of ribosome dysfunction. (2010, background): “In a phase 2 trial in low-risk MDS patients with 5q deletions, lenalidomide treatment decreased transfusion requirement in 76% of patients, and 61% of patients had a complete cytogenetic response.28 Lenalidomide has many biologic activities, including the promotion of erythropoiesis, modulation of c”